Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from RepliCel Life Sciences ( (TSE:RP) ).
RepliCel Life Sciences announced the completion of an asset sale and royalty transaction with 1456390 B.C. Ltd., a company controlled by RepliCel’s CEO, Andrew Schutte. This transaction involves licensing certain patent rights and selling related assets, with RepliCel receiving an 8% royalty on gross profits. The company also announced plans to delist from the TSX Venture Exchange and other exchanges, continuing as a reporting issuer in certain Canadian provinces. The agreement includes provisions for future dividends from royalty payments, subject to specific conditions.
More about RepliCel Life Sciences
RepliCel Life Sciences operates in the biotechnology industry, focusing on autologous cell therapies and the development of programmable injector devices. Their market focus includes products like RCH-01, the NBDS platform, RCI-01, and DermaPrecise RCI-02.
Average Trading Volume: 10,483
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $509.1K
See more data about RP stock on TipRanks’ Stock Analysis page.